is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Evonik introduces antimicrobial acrylic

After four years of development, Evonik introduced an antimicrobial acrylic to the medical device industry at MD&M West, hosting device OEMs and their suppliers at a breakfast event launching the new material. Cyrolite Protect is described by the company as an acrylic-based multipolymer compound designed for FDA-regulated Class I or Class II medical devices and covered by 510(k) PMN submission.

Evonik's initial target applications include luer connectors, spikes, Y-sites, check valves, and filter housings. After consulting its customers, the company tested the new compounds to a Japanese standard, the JIS Z 2801 protocol. Under this test method, parts made from the resin are placed in a petri dish with live bacteria for either 24- or 96-hour durations. The bacteria tested were staphylococcus aureus, klebsiella pneumoniae, pseudomonas aeruginosa, and staphylococcus epidermis, giving results against two gram-positive and two gram-negative bacteria.

Against all four bacteria and in the 24-hour and 96-hour tests, the antimicrobial material achieved a kill rate of log 4, meaning that 99.99% of the bacteria within the petri dish was gone by the end of the test.

Cyrolite Protect comes as a precompounded pellet with silver as the active antimicrobial agent. In a final component, the resin is translucent with a slight green tint, a property that Evonik officials say will help distinguish components made from the resin.

Peter Colburn, director business development & innovation for molding compounds/performance polymers, told PlasticsToday that in a hospital setting, IV's have to be changed every four days, which fits within Cyrolite Protect's 96-hour antimicrobial test performance. The material is compounded by Evonik at its facility in Wallingford, CT and is currently patent pending.

Colburn and Lawrence Gabriel, business development manager molding compounds/performance polymers, said that with Cyrolite Protect the company makes a clear, tested statement about its antimicrobial activity compared to antimicrobial "claims" made by some competitors. —Tony Deligio

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.